Dr Costas Yannakou
Clinical (Associate Professor)
Department of Clinical Pathology
19 Scholarly works
0 Projects
HIGHLIGHTS
2026
Journal article
An evaluation of elranatamab for the treatment of myeloma: current evidence for treating relapsed/refractory disease and future directions
DOI: 10.1080/14712598.2026.26340552025
Journal article
Personalized Immunotherapy for T Cell Lymphomas: From Immune Escape to Precision Therapeutics
DOI: 10.3390/jpm151105602025
Journal article
Glofitamab Combined with Pola-R-CHP or R-CHOP as First Therapy in Younger Patients with High-Risk Large B-Cell Lymphoma: Results from the COALITION Study
DOI: 10.1200/JCO-25-004812025
Journal article
Circulating Tumour DNA Is a Biomarker of Response in Angioimmunoblastic T-Cell Lymphoma
DOI: 10.3390/ijms261467192025
Journal article
Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
DOI: 10.1200/JCO-24-015492025
Journal article
An evaluation of odronextamab for the treatment of multiple subtypes of relapsed/refractory B-cell non-Hodgkin lymphoma
DOI: 10.1080/14712598.2025.24796312024
Conference Proceedings
Pharmacokinetic and Dose Response Relationships Observed in the Study “a Phase 1, Open- Label Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PTX-100 in Patients with Advanced and Relapsed/Refractory T Cell Lymphoma”
DOI: 10.1182/blood-2024-207750
RECENT SCHOLARLY WORKS
2023
Journal article
Capturing the lived experiences of women with lymphoma in pregnancy: a qualitative study
DOI: 10.1080/10428194.2022.21483762021
Conference Proceedings
Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Interim Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02)
DOI: 10.1182/blood-2021-1518712021
Journal article
Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2021
DOI: 10.1111/imj.15588